Intellectual Property Protection

Australia has one of the strongest and most stable intellectual property systems in the world.

What are the major strengths of the Australian intellectual property system?

According to the International Property Rights Index, Australia’s intellectual property system currently ranks as the 11th most secure in the world (out of 142 countries).

Broadly deemed patentable subject matter

In Australia, patents are available for a wide range of therapeutic inventions such as new active ingredients, new formulations, isolated forms of (therapeutically useful) natural products and new methods of treatment.

Patent term extensions

In compliance with Article 33, World Trade Organization’s Agreement on Trade- Related Aspects of Intellectual Property Rights, Australia grants (standard) patent owners 20 years of protection.

Since 1999, Australia also grants owners of patents covering pharmaceutical substances the right to seek patent term restoration, called an “extension of term”. Apply for up to five years of patent term extension to compensate for the process of obtaining regulatory approval, in order to achieve an effective patent life of up to 15 years from the date of first entry of a new pharmaceutical substance on the Australian Register of Therapeutic Goods.

Data exclusivity

Australia provides five years data exclusivity to new pharmaceutical products,  preventing competitors from relying on proprietary safety and efficacy data for five years, beginning from the date of a new medicine or vaccine’s first inclusion on the Australian Register of Therapeutic Goods.

Innovation patents

In Australia, an innovation patent lasts up to eight years – compared to 20 years for standard patents – and is designed to protect inventions that do not meet the inventive threshold required for standard patents. An innovation patent is a relatively quick and inexpensive way to obtain intellectual property protection for a new medical device or pharmaceutical substance, method or process.

People who read this were also interested in:
>  Benefit from our rapid clinical trials approval system 
>  What are the attractive tax incentives and who is eligible?